Development
AstraZeneca PLC
AZN
$73.01
$0.130.18%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 5.96B | 5.90B | 6.16B | 4.71B | 3.29B |
| Total Depreciation and Amortization | 4.85B | 4.91B | 5.00B | 5.19B | 5.18B |
| Total Amortization of Deferred Charges | 280.00M | 292.00M | 292.00M | 292.00M | 292.00M |
| Total Other Non-Cash Items | -1.04B | -1.18B | -1.89B | -2.68B | -2.71B |
| Change in Net Operating Assets | 300.00M | 449.00M | 619.00M | 2.20B | 3.76B |
| Cash from Operations | 10.35B | 10.36B | 10.18B | 9.71B | 9.81B |
| Capital Expenditure | -1.36B | -1.21B | -1.14B | -1.12B | -1.09B |
| Sale of Property, Plant, and Equipment | 132.00M | 396.00M | 408.00M | 407.00M | 282.00M |
| Cash Acquisitions | -1.10B | -1.05B | -1.12B | -1.22B | -1.04B |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1.74B | -1.37B | -1.91B | -2.10B | -1.12B |
| Cash from Investing | -4.06B | -3.24B | -3.76B | -4.04B | -2.96B |
| Total Debt Issued | 3.98B | 3.62B | 3.65B | 3.70B | 74.00M |
| Total Debt Repaid | -5.21B | -4.92B | -3.66B | -3.51B | -1.52B |
| Issuance of Common Stock | 33.00M | 30.00M | 29.00M | 28.00M | 29.00M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -4.48B | -4.48B | -4.46B | -4.44B | -4.36B |
| Other Financing Activities | -886.00M | -886.00M | -890.00M | -890.00M | -1.05B |
| Cash from Financing | -6.57B | -6.63B | -5.34B | -5.11B | -6.82B |
| Foreign Exchange rate Adjustments | -60.00M | -60.00M | -92.00M | -82.00M | -80.00M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -346.00M | 433.00M | 991.00M | 475.00M | -55.00M |